TerminatedPhase 3

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Stopped: As the feeder study (AZES) was stopped for futility after an independent assessment, this trial was also stopped.

United States421 participantsStarted 2017-03-15

Plain-language summary

This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants previously enrolled in AMARANTH (NCT02245737) who meet eligibility criteria for delayed-start I8D-MC-AZFD. Exclusion Criteria: * Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.

What they're measuring

Change From Baseline Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)

Timeframe: AZES Baseline through AZFD Week 26

Trial details

NCT IDNCT02972658

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-10-02

Results submitted2019-06-11

View on ClinicalTrials.gov More Alzheimer's Disease trials